Tech Company Financing Transactions
CORE Biomedicine Funding Round
CORE Biomedicine, based in Allston, scored $21 million from Elikon Venture, UTokyo Innovation Platform and CD Capital.
Transaction Overview
Company Name
Announced On
7/28/2026
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Series A
Investors
Elikon Venture (Lead Investor)
UTokyo Innovation Platform (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its lead programs through discovery and early clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
127 Western Ave
Allston, MA 02134
USA
Allston, MA 02134
USA
Phone
Undisclosed
Website
Email Address
Overview
At CORE Biomedicine, we are redefining precision oncology -- developing next-generation cancer therapeutics that go beyond genomic alterations to address the fundamental biological programs driving tumor survival and progression. Mission: CORE Biomedicine is a preclinical-stage oncology company dedicated to innovating precision medicine therapeutics by targeting core lineage-dependent pathways in cancer. Traditional genomics-centric approaches capture only part of what sustains tumors. We are committed to unlocking the deeper biology that governs cancer identity and therapy resistance -- and to translating those insights into life-changing medicines.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/28/2026: FireAI venture capital transaction
Next: 7/28/2026: Ominimo venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document tech company VC transactions. VC investment data records reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








